Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Vinay Patel, an innovative pharmacist who's set out to ...

That scuppered Sanofi's plans for filing tolebrutinib in PPMS, and the FDA has now slammed the brakes on its efforts to get ...

To begin to close the equity gap in diabetes, we must commit to designing therapies that account for the practical realities ...

Bevacizumab has been sold as Avastin by originator Roche for many years and used by the NHS for various forms of cancer, with ...

Life science marketing is changing, and with it our need for personalised engagement strategies. While omnichannel marketing ...

Screenshot of PathAI's AIM-MASH AI Assist in action. An artificial intelligence model developed by PathAI – used to help diagnose metabolic dysfunction associated steatohepatitis (MASH) from liver ...

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics for the treatment of ...

Trusted Johnson & Johnson brands including Tylenol, Aveeno, Neutrogena, Listerine, and Band-Aid are set to fall under the new, independent company name in a next-chapter move of repurposing and ...

The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune diseases.

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long-term data ...

There's no doubt that self-injection devices have transformed the lives of people with chronic diseases like diabetes, making it easier to receive treatment, whilst also reducing risks like ...